Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

被引：0
|
作者：
Hedrick, E.
Kozloff, M.
Hainsworth, J.
Badarinath, S.
Cohn, A.
Flynn, P.
Dong, W.
Suzuki, S.
Sugrue, M.
Grothey, A.
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Florida Oncol Associates, Jacksonville, FL USA
[5] Rocky Mt Canc Ctr, Denver, CO USA
[6] Abbott NW Hosp, Minneapolis, MN 55407 USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3536
引用
收藏
页码：155S / 155S
页数：1
相关论文
共 50 条
  • [31] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [32] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [33] CLINICAL OUTCOMES WITH FIRST-LINE BEVACIZUMAB AND CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER AND A HISTORY OF DIABETES: RESULTS FROM THE ARIES OBSERVATIONAL COHORT STUDY
    Bendell, J.
    Cohn, A.
    Mun, Y.
    Fish, S.
    Sommer, N.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [34] Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen. results from the brite observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Feng, S.
    Purdie, D.
    Grothey, A.
    Sargent, D.
    Berlin, J.
    Kabbinavar, F.
    Dong, W.
    Flynn, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [35] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    Lopez, R.
    Salgado, M.
    Reboredo, M.
    Grande, C.
    Mendez, J. C.
    Jorge, M.
    Romero, C.
    Quintero, G.
    de la Camara, J.
    Candamio, S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1536 - 1541
  • [36] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    R López
    M Salgado
    M Reboredo
    C Grande
    J C Méndez
    M Jorge
    C Romero
    G Quintero
    J de la Cámara
    S Candamio
    British Journal of Cancer, 2010, 103 : 1536 - 1541
  • [37] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [38] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [39] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
    Antonuzzo, Lorenzo
    Giommoni, Elisa
    Pastorelli, Davide
    Latiano, Tiziana
    Pavese, Ida
    Azzarello, Domenico
    Aieta, Michele
    Pastina, Ilaria
    Di Fabio, Francesca
    Bertolini, Alessandro
    Corsi, Domenico Cristiano
    Mogavero, Selene
    Angelini, Valentina
    Pazzagli, Mario
    Di Costanzo, Francesco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
  • [40] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
12345